Melanotan II: a beautifully designed molecule with an ugly case-report file

The short version

Melanotan II is a small, lab-designed peptide that copies a natural hormone the body uses to switch on pigment production. Because it activates that same switch directly, skin can darken without any sunlight at all — which is why it exists, and why it is studied.

It is genuinely clever chemistry. Researchers at the University of Arizona took a fragment of the natural hormone, cyclized it into a ring and swapped one amino acid for its mirror image, producing a molecule far more potent and far harder for the body's enzymes to break down than the original.

The problem is everything else the switch controls. The same receptor family governs appetite, sexual arousal and blood-vessel tone, so activating it non-selectively produces a long list of effects nobody was aiming at ^[15][16]. No Phase II or Phase III trial was ever completed for this compound, its controlled human data come from tiny early-phase studies, and its recent literature is largely case reports: reversible pigmentation of the mouth ^[12], renal infarction ^[14], and more besides. It is approved nowhere, for anything.

What it is

Melanotan II is a cyclic, lactam-bridged seven-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH), designed in the late 1980s by Hruby and Hadley for superpotent, enzymatically resistant melanotropic activity. It is a truncated, cyclized, D-phenylalanine-substituted derivative of the hormone's active core, and it circulates in research supply under names including MT-2, MT-II and MTII.

Two confusions are worth clearing up immediately, because both are common and both matter:

• Melanotan II is not melanotan I. The linear analog afamelanotide is a separately developed, regulator-approved melanocortin therapy for a rare light-sensitivity disorder. That approval and its controlled-trial safety data do not transfer to melanotan II ^[15].
• Melanotan II is not the approved sexual-function drug derived from it. Bremelanotide, also known as PT-141, is a distinct downstream analog that went through pivotal trials and reached market ^[15]. Melanotan II did not.

What remains is an unapproved research chemical with no completed late-phase development, sold and self-administered outside any regulatory system.

How it works

Melanotan II is a non-selective agonist of the melanocortin receptors, activating MC1R through MC5R rather than picking one. That non-selectivity is the whole story of its effect profile.

At MC1R on melanocytes — the pigment-making cells in skin — activation raises intracellular cAMP and drives the PKA-CREB-MITF cascade, which upregulates the enzyme tyrosinase and shifts pigment synthesis toward eumelanin. Skin and hair darken without any ultraviolet exposure, because the step UV normally triggers has been bypassed.

At MC4R and MC3R in the hypothalamus and mesolimbic system, activation drives appetite suppression, pro-erectile effects and changes in sexual motivation. This is not a side channel; it is the same signal. A mouse study microinjecting the compound directly into the nucleus accumbens at 0.1 to 1 nmol per side significantly decreased both food consumption and the effort animals would expend to obtain food, without producing conditioned taste aversion or changing metabolic rate — evidence that the appetite effect is a genuine motivational signal rather than nausea-driven avoidance ^[13].

MC5R involvement in exocrine and sebaceous gland function rounds out a receptor profile that touches pigment, appetite, sexual function, energy balance and vascular tone at once.

What the research shows

The controlled human literature is small, old, and about erections rather than skin.

The one controlled trial of note. In a double-blind, placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction, subcutaneous melanotan II at 0.025 mg/kg produced clinically apparent erections in 8 of the 10; mean duration of greater-than-80% tip rigidity was 38.0 minutes against 3.0 minutes on placebo, a statistically significant difference, with transient nausea, stretching and yawning that required no treatment ^[16]. Ten men. One crossover. That is the high-water mark of controlled evidence for this compound.

The developmental history. A review of melanocortin peptide therapeutics documents that both melanotan I and melanotan II were patented and tested clinically — the linear analog for skin tanning, melanotan II for male erectile dysfunction — and that a further melanotan II-derived analog, bremelanotide, advanced toward pivotal trials and commercialization for sexual dysfunction in both sexes ^[15]. The lineage matters: the successful drugs in this family are the ones that went through regulated development. Melanotan II is the branch that did not.

The appetite mechanism. The nucleus accumbens work in male C57BL/6J mice establishes that mesolimbic melanocortin signalling selectively reduces appetite and food motivation without aversion or metabolic-rate change ^[13].

The recent literature is safety reporting, not efficacy. A 2026 case report documents reversible oral-mucosal pigmentation in a man who self-administered 400 micrograms subcutaneously every other day for 64 days, 12.8 mg cumulative: brown pigmentation developed on the attached gingiva of both jaws and on the buccal mucosa, with buccal pigmentation beginning to fade 28 days after stopping while gingival pigmentation persisted at reduced intensity three months later ^[12]. A nephrology case report with literature review describes renal infarction most likely attributable to melanotan II, noting that rhabdomyolysis and renal failure with this compound had been described previously, and that both a thrombotic pharmacological influence and a possible direct toxic effect on renal tissue must be considered ^[14].

No validated human pharmacokinetic half-life has been published for melanotan II itself; figures in circulation are extrapolated from rodent data and from the related linear analog.

Reported effects, cautions & safety

What follows first is community-reported material — anecdotal, not clinical evidence. It comes from peptide-user forums, harm-reduction commentary and a published qualitative study of online discussions, describes unsupervised self-administration of unregulated product, and carries no verified dose.

The effect people describe seeking is rapid darkening within days, reached with far less sun exposure than they would otherwise need. Alongside it, very commonly reported: markedly reduced hunger, sometimes within the first hour and sometimes with weight loss, which users split on as welcome or off-putting; and, among men, a surge in libido with spontaneous erections beginning after the first or second dose, described by some as unwelcome and awkward rather than desirable. Women also report heightened arousal. A distinctive and frequently mentioned sensation is repeated stretching and yawning in the period after injecting — the same triad of nausea, stretching and yawning the controlled study recorded ^[16].

The reported downsides are extensive and, unusually for community reporting, line up closely with the published harms. Very commonly described: nausea, sometimes with vomiting, worst in the first days; darkening of existing moles and freckles, often the first visible change and described as disproportionate to the surrounding skin; and new moles appearing during use, sometimes many at once, which users say is what prompted them to see a doctor. Commonly described: facial flushing and heat within minutes; patchy, blotchy or unnaturally persistent colour, sometimes with an orange or grey cast; selective darkening of lips, gums, old scars, underarm and genital skin; a run-down flu-like tiredness in the first days; and injection-site reactions. After stopping, colour is reported to fade slowly and unevenly over weeks to months, with moles and freckles sometimes remaining darker than before. Some users believe their colour protects them from burning; that is a belief, not a demonstrated protection, and burns are still reported.

The cited and case-documented cautions are the serious part of this page:

• New, changing or darkening moles, and melanoma risk. As a non-selective melanocortin agonist acting at MC1R, the compound drives melanocyte activity across the whole skin. Case reports describe eruptive new nevi, dysplastic nevi, and darkening or change in existing moles after use; further case reports document melanoma and melanoma in situ arising in users, and dermoscopy studies show measurable changes in melanocytic lesions during use. Any new or changing mole during or after use warrants prompt dermatological assessment.
• Rhabdomyolysis and acute kidney injury. A published case links melanotan II injection to systemic toxicity with rhabdomyolysis — severe muscle breakdown — and a separate case with literature review describes renal infarction associated with its use ^[14].
• Priapism. Because melanocortin agonism promotes erections, several case reports describe priapism, a prolonged and painful erection, following injection, including after apparent overdose. It is a urological emergency that can cause permanent damage if not treated quickly.
• Posterior reversible encephalopathy syndrome. A case report describes this neurological condition, involving brain swelling with headache, seizures, visual disturbance and raised blood pressure, in association with melanotan use — consistent with the compound's reported effects on blood pressure and vascular tone.
• Cardiovascular and gastrointestinal effects. Preclinical work on the hemodynamic actions of alpha-MSH analogs shows melanocortin agonists can raise blood pressure, an effect worsened in animal studies by impaired nitric oxide signalling. Together with the very commonly reported nausea, this is a meaningful and poorly characterised profile in people using unregulated material.
• The vial itself is an unknown. Analytical studies of melanotan products bought online repeatedly find inaccurate labelling, variable or unverifiable peptide content and impurities, and the compound appears in surveys of falsified and black-market injectables — forensic work on seized and online product marketed under the tabloid "Barbie drug" nickname confirms wide variability. Without quality control, the identity, quantity, purity and sterility of the contents are all unknown, which compounds every risk above.
• No approval, unknown long-term safety. Melanotan II has never been approved by any regulator for any use and never completed late-phase trials, so its long-term safety in humans is simply unknown ^[15]. Regulators and dermatology bodies have specifically warned against melanotan products.

Where it fits in skin & aesthetics research

Melanotan II belongs on this desk because pigmentation is part of the skin-and-aesthetics category, and because it is the cleanest available demonstration that a well-understood mechanism is not a safety argument. The MC1R pathway it exploits is textbook pharmacology, described in detail and reproducible. That did not prevent the case-report file.

It also sits at the opposite pole from GHK-Cu on every axis that matters: route, regulatory status, reversibility, and the ratio of documented benefit to documented harm. The comparison page sets that contrast out explicitly. Anyone reading this page for a protocol has misread it — the literature here is a warning file, not a manual.